Financial Performance - The company's revenue for the year ended December 31, 2025, was SGD 18,586,000, representing a 77.8% increase from SGD 10,459,000 in 2024[4] - Gross profit for the same period was SGD 3,318,000, compared to SGD 228,000 in 2024, indicating a significant improvement[4] - The company reported a net loss of SGD 612,000 for 2025, a reduction from a net loss of SGD 2,631,000 in 2024, showing progress in financial performance[5] - The group recorded a loss of approximately SGD 612,000 and SGD 2,631,000 for the years ending December 31, 2025, and December 31, 2024, respectively[11] - The company reported a loss before tax of SGD 600,000 for 2025, compared to a loss of SGD 2,785,000 in 2024, indicating a significant improvement[34] - The net loss for FY2025 was significantly reduced to about SGD 0.6 million from SGD 2.6 million in FY2024, attributed to increased revenue contributions from diversified business sectors[47] Assets and Liabilities - Total assets decreased to SGD 6,407,000 in 2025 from SGD 6,491,000 in 2024, reflecting a slight decline in asset management[6] - Current liabilities increased to SGD 6,048,000 in 2025 from SGD 3,550,000 in 2024, indicating a rise in short-term financial obligations[6] - Non-current liabilities decreased significantly to SGD 1,366,000 in 2025 from SGD 3,077,000 in 2024, indicating improved long-term financial stability[7] - The company's equity attributable to owners decreased to SGD 1,524,000 in 2025 from SGD 2,141,000 in 2024, reflecting a decline in shareholder value[7] - The total liabilities rose to SGD 7,414,000 in 2025 from SGD 6,627,000 in 2024, primarily due to increased component liabilities[26] Cash Flow and Liquidity - The company's cash and cash equivalents decreased to SGD 1,190,000 in 2025 from SGD 1,779,000 in 2024, highlighting liquidity challenges[6] - Current liabilities due within one year as of December 31, 2025, amount to approximately SGD 6,048,000, while cash and bank balances are around SGD 1,190,000[11] - Current ratio decreased to approximately 1.1 times as of December 31, 2025, from 1.8 times in FY2024, due to a reduction in cash and cash equivalents and an increase in borrowings[61] Revenue Segments - Total segment revenue for the year ending December 31, 2025, is SGD 18,586,000, with the medical components segment contributing SGD 10,580,000[23] - Major customer A contributed SGD 10,589,000 to total revenue in 2025, up from SGD 7,859,000 in 2024, while customer B's contribution dropped below 10% of total revenue[27] - Revenue from the mainland China market surged to SGD 6,552,000 in 2025, compared to SGD 841,000 in 2024, highlighting significant market expansion[28] Operational Strategy - The company continues to focus on manufacturing and selling disposable medical devices and providing data solutions, indicating ongoing commitment to core business areas[8] - The group plans to raise additional funds through equity financing and long-term debt financing to cover operational costs and repay existing debts[13] - The group aims to negotiate with lenders to extend repayment terms for loans and payables until sufficient operational funds are available[13] - The company introduced new revenue streams from data solutions and hotel-related businesses, diversifying its income sources[47] Expenses and Costs - Research and development expenses decreased to SGD 403,000 in 2025 from SGD 559,000 in 2024, indicating a potential shift in strategic focus[31] - Administrative expenses rose by approximately SGD 0.5 million or 18.5% from about SGD 2.7 million in FY2024 to about SGD 3.2 million in FY2025, mainly due to increased professional service costs related to business expansion[58][59] - Financial costs increased from approximately SGD 0.2 million in FY2024 to approximately SGD 0.3 million in FY2025, attributed to accrued interest from a shareholder loan[60] Shareholder Information - The average number of ordinary shares issued increased to 81,846,000 in 2025 from 74,035,000 in 2024, affecting the calculation of basic loss per share[36] - The company raised approximately SGD 9.7 million from the issuance of new ordinary shares at a net price of about SGD 0.071 per share[72][73] - No final dividend was recommended for the year ending December 31, 2025[76] Governance and Compliance - The company has adhered to the corporate governance code as per GEM listing rules, except for the separation of roles between the Chairman and CEO, which is currently held by Mr. Pan[88] - All directors confirmed compliance with the trading standards for securities transactions during the fiscal year 2025, with no known non-compliance events[89] - The audit committee, consisting of three independent non-executive directors, has reviewed the audited financial information and confirmed compliance with applicable accounting standards and GEM listing rules[93] Market Conditions - The company remains cautious about geopolitical tensions, inflationary pressures, and global economic fluctuations impacting its operations[48] - There is significant uncertainty regarding the management's ability to achieve the expected results from the implemented measures, which may affect the group's ability to continue as a going concern[12]
加和国际控股(08513) - 2025 - 年度业绩